Chinese (SSE) Clinical Research and Equipment Industry Analysis

Industry Valuation and Performance

Has the Chinese Clinical Research and Equipment Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 27 May 2026	CN¥577.0b	CN¥98.7b	CN¥21.7b	55.5x	26.6x	5.8x
Fri, 24 Apr 2026	CN¥587.3b	CN¥95.1b	CN¥20.8b	60.8x	28.2x	6.2x
Sun, 22 Mar 2026	CN¥480.2b	CN¥94.5b	CN¥18.7b	57.2x	25.7x	5.1x
Tue, 17 Feb 2026	CN¥608.5b	CN¥94.4b	CN¥18.6b	68.1x	32.8x	6.4x
Thu, 15 Jan 2026	CN¥651.4b	CN¥94.3b	CN¥18.5b	64x	35.2x	6.9x
Sat, 13 Dec 2025	CN¥564.4b	CN¥94.3b	CN¥18.5b	63.6x	30.5x	6x
Mon, 10 Nov 2025	CN¥570.6b	CN¥94.3b	CN¥18.5b	65.3x	30.8x	6.1x
Wed, 08 Oct 2025	CN¥639.6b	CN¥92.1b	CN¥17.4b	70.8x	36.7x	6.9x
Fri, 05 Sep 2025	CN¥596.4b	CN¥92.5b	CN¥17.6b	57.5x	33.9x	6.4x
Sun, 03 Aug 2025	CN¥567.3b	CN¥91.6b	CN¥17.9b	58.8x	31.7x	6.2x
Tue, 01 Jul 2025	CN¥444.1b	CN¥89.8b	CN¥15.4b	49.8x	28.9x	4.9x
Thu, 29 May 2025	CN¥393.5b	CN¥89.1b	CN¥15.3b	43x	25.7x	4.4x
Sat, 26 Apr 2025	CN¥379.9b	CN¥88.2b	CN¥13.6b	39.6x	28x	4.3x
Mon, 24 Mar 2025	CN¥439.8b	CN¥88.4b	CN¥14.6b	42.3x	30.2x	5x
Wed, 19 Feb 2025	CN¥412.6b	CN¥88.1b	CN¥11.2b	41.8x	36.7x	4.7x
Fri, 17 Jan 2025	CN¥353.2b	CN¥88.1b	CN¥11.2b	36.3x	31.4x	4x
Sun, 15 Dec 2024	CN¥388.6b	CN¥87.8b	CN¥11.2b	40.1x	34.7x	4.4x
Tue, 12 Nov 2024	CN¥410.5b	CN¥87.8b	CN¥11.2b	44.8x	36.7x	4.7x
Thu, 10 Oct 2024	CN¥394.6b	CN¥88.2b	CN¥12.4b	35.5x	31.9x	4.5x
Sat, 07 Sep 2024	CN¥274.1b	CN¥87.1b	CN¥12.3b	27.9x	22.3x	3.1x
Mon, 05 Aug 2024	CN¥301.0b	CN¥87.6b	CN¥12.6b	27.9x	24x	3.4x
Wed, 03 Jul 2024	CN¥274.6b	CN¥88.3b	CN¥13.4b	24.3x	20.5x	3.1x
Fri, 31 May 2024	CN¥307.5b	CN¥88.3b	CN¥13.4b	27.5x	23x	3.5x
Sun, 28 Apr 2024	CN¥317.5b	CN¥90.2b	CN¥14.4b	30.4x	22x	3.5x
Tue, 26 Mar 2024	CN¥345.9b	CN¥90.4b	CN¥15.6b	32.4x	22.2x	3.8x
Thu, 22 Feb 2024	CN¥355.5b	CN¥91.1b	CN¥16.1b	31.2x	22.1x	3.9x
Sat, 20 Jan 2024	CN¥452.3b	CN¥91.1b	CN¥16.1b	35.4x	28.1x	5x
Mon, 18 Dec 2023	CN¥479.2b	CN¥91.1b	CN¥16.1b	37.3x	29.8x	5.3x
Wed, 15 Nov 2023	CN¥550.9b	CN¥91.1b	CN¥16.1b	40.1x	34.3x	6x
Fri, 13 Oct 2023	CN¥544.2b	CN¥92.0b	CN¥18.3b	36.4x	29.7x	5.9x
Sun, 10 Sep 2023	CN¥470.0b	CN¥91.9b	CN¥18.3b	32.3x	25.7x	5.1x
Tue, 08 Aug 2023	CN¥481.8b	CN¥91.8b	CN¥18.5b	34.8x	26.1x	5.2x
Thu, 06 Jul 2023	CN¥460.3b	CN¥91.3b	CN¥18.5b	34.8x	24.9x	5x
Sat, 03 Jun 2023	CN¥500.0b	CN¥91.3b	CN¥18.5b	38.6x	27.1x	5.5x

Current Industry PE

Investors are relatively neutral on the Chinese Life Sciences Tools and Services industry at the moment, indicating that they anticipate long term growth rates to remain steady.

The industry is trading close to its 3-year average PE ratio of 28.7x.

The 3-year average PS ratio of 5.0x is lower than the industry's current PS ratio of 5.8x.

Past Earnings Growth

The earnings for companies in the Life Sciences Tools and Services industry have grown 5.6% per year over the last three years.
Revenues for these companies have grown 2.6% per year.
This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Chinese Clinical Research and Equipment compare with similar industries?


CN Market	-0.16%
Healthcare	-3.22%
Life Sciences	-0.14%
Clinical Research and Equipment	-0.14%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
688222 HitGen	CN¥31.65	8.9% +CN¥1.0b	109.0%	PE99.4x
688131 Shanghai Haoyuan Chemexpress	CN¥78.16	3.7% +CN¥587.5m	112.7%	PE67.6x
301096 Hangzhou Bio-Sincerity Pharma-TechLtd	CN¥64.60	3.6% +CN¥241.8m	64.8%	PS11.9x
688068 Beijing Hotgen Biotech	CN¥85.86	2.4% +CN¥176.7m	-23.0%	PS17.7x

Company

Last Price

Valuation

688222 HitGen

CN¥31.65

8.9%
+CN¥1.0b

109.0%

PE99.4x

688131 Shanghai Haoyuan Chemexpress

CN¥78.16

3.7%
+CN¥587.5m

112.7%

PE67.6x

301096 Hangzhou Bio-Sincerity Pharma-TechLtd

CN¥64.60

3.6%
+CN¥241.8m

64.8%

PS11.9x

688068 Beijing Hotgen Biotech

CN¥85.86

2.4%
+CN¥176.7m

-23.0%

PS17.7x

MGI Tech Co., Ltd. Showcases Next-Generation Laboratory Automation and Multi-Omics Solutions at SLAS 2026

MGI Tech Co., Ltd. presented its latest advancements in laboratory automation and integrated workflow solutions at SLAS 2026 in Vienna, Austria. At this year's event, MGI Tech highlighted a portfolio of intelligent automation and multi-omics solutions designed to accelerate research efficiency, simplify complex workflows, and empower emerging applications in proteomics and integrated laboratory automation. As an extension of the PrepALL platform, PrepALL-pP8G expands its application into the field of single-cell proteomics, primarily for sample pretreatment. A key attribute of the PrepALL platform is its inherent flexibility, allowing seamless integration with external devices to broaden its application scope, of which the PrepALL-pP8G is a prime example. Designed to highly automate and streamline complex proteomics workflows, the system combines thermal inkjet printing technology with high-precision ultra-low volume dispensing to enable a fully integrated workflow from single-cell sorting to proteomics sample preparation. The official European launch is expected in the second half of this year. Featuring 640 independent parallel nozzles and advanced AI-assisted camera vision recognition, the PrepALL-pP8G enables ultra-high throughput processing of 384-well plates in just minutes while preserving cell viability and protein integrity through gentle, electrical-deflection-free sorting. The platform supports label-free, labeled, and conventional proteomics workflows, making it suitable for applications including tumor heterogeneity research, rare cell analysis, organoid and stem cell research, and multi-omics integration. Making its first international debut, MGI Tech also presented the SIRO48, an advanced fully automated sample processing system designed to deliver a "Sample In, Report Out" solution that accelerates and simplifies complex sample processing workflows. The system integrates nucleic acid purification, fragmentation, end repair, adapter ligation, PCR amplification, and library purification & quality control in a single workflow. Engineered to evolve from step-by-step manual operations to integrated full-process closed loop, multi-step manual intervention to full-process unattended execution, and low-throughput single-sample processing to high-throughput parallel processing of 48 samples, it is purpose-built for seamless integration into real-world clinical molecular diagnosis, public health prevention and control, and life science research scenarios. This system enables a transformative leap in sequencing library preparation—from "isolated manual operations" to "full-chain intelligent automation". MGI Tech was also showcasing the PMIF VisiOmics (PMIF-20RS), a fully automated staining and imaging system making its European debut. It leverages multiplex immune fluorescence (mIF) technology to capture precise spatial protein expression data in tissue sections. Integrated with an AI-powered analysis platform for accurate cell segmentation, phenotyping, and spatial mapping, it provides a complete workflow solution for applications in tumor classification, prognosis, tumor microenvironment analysis, and translational research. The official European launch of VisiOmics is also expected to take place in the second half of this year.

Chinese (SSE) Clinical Research and Equipment Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

Dividend of CN¥1.58 announced

MGI Tech Co., Ltd. Showcases Next-Generation Laboratory Automation and Multi-Omics Solutions at SLAS 2026

Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 12, 2026

Beijing Hotgen Biotech Co., Ltd. (SHSE:688068) announces an Equity Buyback for CNY 100 million worth of its shares.

Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) announces an Equity Buyback for CNY 1,000 million worth of its shares.

Consensus EPS estimates increase by 17%, revenue downgraded

New minor risk - Financial data availability

Shanghai InnoStar Bio-tech Co., Ltd., Annual General Meeting, May 29, 2026

First quarter 2026 earnings released: EPS: CN¥0.10 (vs CN¥0.07 in 1Q 2025)

Full year 2025 earnings released: CN¥0.91 loss per share (vs CN¥0.09 profit in FY 2024)

First quarter 2026 earnings released: EPS: CN¥0.24 (vs CN¥0.27 in 1Q 2025)

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind